We analyzed whether the DPP-4 inhibitor, which increases GLP-1 levels (95), as well as an agonist against the GLP-1 receptor, improves skeletal muscle abnormalities and exercise intolerance in HF model mice. The gene discussed is GCG; the disease is hydrops fetalis.